Association between tumor necrosis factor-α (TNF-α) promoter −308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis
暂无分享,去创建一个
D. Ye | Jian-hua Xu | F. Pan | Tianchen Zhang | Jing Gao | Li Zhang | Z. Duan | Z. Zeng | Guixing Li | Sheng Wang | Shengqian Xu | Shengqian Xu | Zhenhua Duan
[1] S. Bae,et al. Associations Between Tumor Necrosis Factor-α (TNF-α) −308 and −238 G/A Polymorphisms and Shared Epitope Status and Responsiveness to TNF-α Blockers in Rheumatoid Arthritis: A Metaanalysis Update , 2010, The Journal of Rheumatology.
[2] Pilar Barrera,et al. Tumour necrosis factor α −308G→A polymorphism is not associated with response to TNFα blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis , 2009, Annals of the rheumatic diseases.
[3] J. Beyene,et al. TNF-α −308 G/A polymorphism and responsiveness to TNF-α blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis , 2009, The Pharmacogenomics Journal.
[4] Anne Barton,et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. , 2008, Human molecular genetics.
[5] P. Miossec,et al. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. , 2008, Arthritis and rheumatism.
[6] P. Ravaud,et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.
[7] Olfert Landt,et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. , 2007, Arthritis and rheumatism.
[8] B. Franke,et al. Pharmacogenetics of anti-TNF treatment in patients with rheumatoid arthritis. , 2007, Pharmacogenomics (London).
[9] I. Georgiou,et al. Combined tumour necrosis factor-alpha and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-alpha therapy and explain controversies of studies based on a single polymorphism. , 2007, Rheumatology.
[10] P. Villiger,et al. The −308 tumour necrosis factor-α gene polymorphism predicts therapeutic response to TNFα-blockers in rheumatoid arthritis and spondyloarthritis patients , 2007 .
[11] Y. Lee,et al. Association of TNF-alpha –308 G/A polymorphism with responsiveness to TNF-α-blockers in rheumatoid arthritis: a meta-analysis , 2006, Rheumatology International.
[12] J. Aguillón,et al. Tumour necrosis factor (TNF)α −308 G/G promoter polymorphism and TNFα levels correlate with a better response to adalimumab in patients with rheumatoid arthritis , 2006 .
[13] J. Aguillón,et al. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. , 2006, Scandinavian journal of rheumatology.
[14] J. Fonseca,et al. Polymorphism at position –308 of the tumour necrosis factor α gene and rheumatoid arthritis pharmacogenetics , 2005, Annals of the rheumatic diseases.
[15] S. Bae,et al. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. , 2005, Rheumatology.
[16] H. Tiwari,et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. , 2004, Arthritis and rheumatism.
[17] A. Aguirre,et al. Tumour necrosis factor‐α (TNF‐α) levels and influence of −308 TNF‐α promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis , 2004 .
[18] N. Balandraud,et al. Polymorphism at the position -308 of TNF-α gene influences outcome of infliximab therapy in rheumatoid arthritis , 2004, Arthritis Research & Therapy.
[19] Y. Mándi,et al. Tumour necrosis factor-alpha and heat-shock protein 70-2 gene polymorphisms in a family with rheumatoid arthritis. , 2004, Acta microbiologica et immunologica Hungarica.
[20] J. Cuenca,et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. , 2004, Scandinavian journal of rheumatology.
[21] Nathalie Balandraud,et al. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. , 2003, Arthritis and rheumatism.
[22] L. Padyukov,et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis , 2003, Annals of the rheumatic diseases.
[23] G. Panayi,et al. Cytokine pathways and joint inflammation in rheumatoid arthritis. , 2001, The New England journal of medicine.
[24] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[25] I. Olkin,et al. Meta-analysis of observational studies in epidemiology - A proposal for reporting , 2000 .
[26] R. Allen. Polymorphism of the human TNF-α promoter — random variation or functional diversity? , 1999 .
[27] R. Allen. Polymorphism of the human TNF-alpha promoter--random variation or functional diversity? , 1999, Molecular immunology.
[28] J. Belaiche,et al. Tumour necrosis factor (TNF) gene polymorphism influences TNF‐α production in lipopolysaccharide (LPS)‐stimulated whole blood cell culture in healthy humans , 1998, Clinical and experimental immunology.
[29] C. Weyand,et al. The molecular basis of rheumatoid arthritis , 1997, Journal of Molecular Medicine.
[30] F. Breedveld,et al. Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease? , 1997, British journal of rheumatology.
[31] M. Homma. [ACR preliminary definition, of improvement in rheumatoid arthritis]. , 1996, Ryumachi. [Rheumatism].
[32] D. Rennie,et al. The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. , 1995, JAMA.
[33] J J Anderson,et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[34] I. Chalmers. The Cochrane Collaboration: Preparing, Maintaining, and Disseminating Systematic Reviews of the Effects of Health Care , 1993, Annals of the New York Academy of Sciences.
[35] M. Feldmann,et al. TNF alpha--a pivotal role in rheumatoid arthritis? , 1992, British journal of rheumatology.
[36] P. Vassalli,et al. The pathophysiology of tumor necrosis factors. , 1992, Annual review of immunology.
[37] F. Epstein,et al. Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.
[38] F. Arnett. Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.
[39] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.